Skip to main content

Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.

Publication ,  Conference
Liu, Y; Chen, Z; Wei, R; Shi, L; He, F; Shi, Z; Jin, T; Xie, R; Wei, B; Chen, J; Fang, H; Zhu, B; Li, Q-J; Wang, P
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

8020 / 8020

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liu, Y., Chen, Z., Wei, R., Shi, L., He, F., Shi, Z., … Wang, P. (2018). Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma. In Journal of Clinical Oncology (Vol. 36, pp. 8020–8020). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.8020
Liu, Yarong, Zhi Chen, Runhong Wei, Lin Shi, Feng He, Zixiao Shi, Tao Jin, et al. “Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.” In Journal of Clinical Oncology, 36:8020–8020. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.8020.
Liu Y, Chen Z, Wei R, Shi L, He F, Shi Z, et al. Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 8020–8020.
Liu, Yarong, et al. “Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 8020–8020. Crossref, doi:10.1200/jco.2018.36.15_suppl.8020.
Liu Y, Chen Z, Wei R, Shi L, He F, Shi Z, Jin T, Xie R, Wei B, Chen J, Fang H, Zhu B, Li Q-J, Wang P. Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 8020–8020.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

8020 / 8020

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences